SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
NICE Approves Seven Digital Cardiac Rehabilitation Technologies for Enhanced Patient Care
Digital cardiac rehabilitation is transforming how patients with cardiovascular disease access vital recovery support, and if you're wondering about the latest NICE recommendations for digital platforms in cardiac rehab, here's the key update. NICE has conditionally approved seven innovative tool...
Repurposing Off-Patent Medicines: Insights from the EU Pilot Initiative
EU Pilot Initiative for Repurposing Off-Patent Medicines: Core Outcomes and Regulatory Support
Repurposing off-patent medicines offers a promising pathway to address unmet medical needs, p...
Innovations in Haematology Cell Therapy at ASH 2025
Advancing Haematology Cell Therapy Innovations at ASH 2025
AstraZeneca is significantly advancing haematology cell therapy with its largest-ever presence at the 67th American Society of Hematology (ASH) Annual Meeting and E...